Gyre Therapeutics (GYRE) Long-Term Debt Repayments (2010 - 2018)
Gyre Therapeutics (GYRE) reported Long-Term Debt Repayments of $5.1 million for Q1 2018, down 24.73% year-over-year from $6.8 million in Q1 2017, and up 1161.04% on a QoQ basis from $403000.0 in Q4 2017.
Gyre Therapeutics (GYRE) has 9 years of Long-Term Debt Repayments data on file, last reported at $5.1 million in Q1 2018.
- Quarterly Long-Term Debt Repayments fell 24.73% year-over-year to $5.1 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $5.1 million (down 64.51% YoY) and the FY2018 annual result came in at $5.1 million, down 64.51% from the prior year.
- Long-Term Debt Repayments grew to $5.1 million in Q1 2018 per GYRE's latest filing, from $403000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $10.3 million in Q4 2016 and bottomed at $218000.0 in Q1 2014.
- The 5-year median for Long-Term Debt Repayments is $634000.0 (2016), against an average of $2.6 million.
- The widest annual swing landed in 2016, when Long-Term Debt Repayments soared 1089.46%; it then plunged 96.07% in 2017.
- Tracing GYRE's Long-Term Debt Repayments over 5 years: stood at $478000.0 in 2014, then surged by 80.54% to $863000.0 in 2015, then soared by 1089.46% to $10.3 million in 2016, then sank by 96.07% to $403000.0 in 2017, then soared by 1161.04% to $5.1 million in 2018.
- Per Business Quant, the three latest GYRE Long-Term Debt Repayments figures stand at $5.1 million (Q1 2018), $403000.0 (Q4 2017), and $282000.0 (Q3 2017).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 5.08 Mn |
| Mar 31, 2018 | 5.08 Mn |
| Dec 31, 2017 | 403,000.00 |
| Dec 31, 2017 | 403,000.00 |
| Sep 30, 2017 | 282,000.00 |
| Sep 30, 2017 | 282,000.00 |
| Jun 30, 2017 | 6.88 Mn |
| Jun 30, 2017 | 6.88 Mn |
| Mar 31, 2017 | 6.75 Mn |
| Mar 31, 2017 | 6.75 Mn |
| Dec 31, 2016 | 10.27 Mn |
| Dec 31, 2016 | 10.27 Mn |
| Sep 30, 2016 | 676,000.00 |
| Sep 30, 2016 | 676,000.00 |
| Jun 30, 2016 | 592,000.00 |
| Jun 30, 2016 | 592,000.00 |
| Mar 31, 2016 | 2.81 Mn |
| Mar 31, 2016 | 2.81 Mn |
| Dec 31, 2015 | 863,000.00 |
| Dec 31, 2015 | 863,000.00 |
| Dec 31, 2014 | 478,000.00 |
| Dec 31, 2014 | 478,000.00 |
| Sep 30, 2014 | 221,000.00 |
| Sep 30, 2014 | 221,000.00 |
| Jun 30, 2014 | 219,000.00 |
| Jun 30, 2014 | 219,000.00 |
| Mar 31, 2014 | 218,000.00 |
| Mar 31, 2014 | 218,000.00 |
| Dec 31, 2013 | 215,000.00 |
| Dec 31, 2013 | 215,000.00 |
| Sep 30, 2013 | 214,000.00 |
| Sep 30, 2013 | 214,000.00 |
| Jun 30, 2013 | 211,000.00 |
| Jun 30, 2013 | 211,000.00 |
| Mar 31, 2013 | 211,000.00 |
| Mar 31, 2013 | 211,000.00 |
| Dec 31, 2012 | 208,000.00 |
| Dec 31, 2012 | 208,000.00 |
| Sep 30, 2012 | 239,000.00 |
| Sep 30, 2012 | 239,000.00 |
| Jun 30, 2012 | 238,000.00 |
| Jun 30, 2012 | 238,000.00 |
| Mar 31, 2012 | 555,000.00 |
| Mar 31, 2012 | 555,000.00 |
| Dec 31, 2011 | 562,000.00 |
| Dec 31, 2011 | 562,000.00 |
| Sep 30, 2011 | 558,000.00 |
| Sep 30, 2011 | 558,000.00 |
| Jun 30, 2011 | 424,000.00 |
| Jun 30, 2011 | 424,000.00 |
| Mar 31, 2011 | 420,000.00 |
| Mar 31, 2011 | 420,000.00 |
| Dec 31, 2010 | 502,000.00 |
| Dec 31, 2010 | 502,000.00 |
| Sep 30, 2010 | 363,000.00 |
| Sep 30, 2010 | 363,000.00 |